Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701231 | 0.92 | PDE5A (0.41) | PDE5AEHMT2SLC29A1KCNH2POLB | |
| SCHEMBL4703066 | 0.86 | PDE5A (0.41) | PDE5ATYRO3KCNH2 | |
| SCHEMBL4705086 | 0.85 | PDE5A (0.48) | PDE5AEHMT2EHMT1SLC29A1KCNH2 | |
| SCHEMBL4705717 | 0.80 | PDE5A (0.40) | PDE5AKCNH2ADORA3ADORA2A | |
| SCHEMBL5484690 | 0.78 | PDE5A (0.38) | PDE5ASELPTYRO3KCNH2ADORA3 | |
| SCHEMBL4700481 | 0.78 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL8295690 | 0.77 | PDE5A (0.45) | PDE5AEHMT2EHMT1KCNH2 | |
| SCHEMBL4705161 | 0.77 | PDE5A (0.45) | PDE5AEHMT2EHMT1KCNH2 | |
| SCHEMBL8295685 | 0.76 | PDE5A (0.38) | PDE5AKCNH2ADORA3ADORA2A | |
| SCHEMBL14290023 | 0.76 | PDE5A (0.45) | PDE5AKCNH2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | PDE5A 724/4885EHMT2 3688/4885EHMT1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.